Aquestive Therapeutics Reports Strong Q1, Secures $150M Debt Facility, Anaphylm Resubmission on Track
AQST has more than doubled off its 52-week low of $2.12.
Summary
Aquestive Therapeutics reported strong Q1 results, securing a new $150 million debt facility to boost liquidity and advance its Anaphylm drug candidate, despite ongoing legal and regulatory hurdles for Libervant.
Key Events · Earnings and Guidance · AQST
-
Strong Q1 Financial Performance
Revenue increased 66% year-over-year to $14.446 million for Q1 2026, and net loss significantly reduced to $(8.057) million from $(22.930) million in Q1 2025.
-
Secured $150M Debt Facility Post-Quarter
On May 12, 2026, the company entered a new five-year term loan facility of up to $150 million. $55 million was funded immediately to repay the existing $45 million 13.5% Senior Secured Notes, significantly improving liquidity and debt terms by shifting to interest-only payments until maturity.
-
Anaphylm NDA Resubmission on Track
Following a Complete Response Letter (CRL) in January 2026, a Type A meeting with the FDA provided clarity, and the company plans to resubmit the New Drug Application (NDA) for Anaphylm in Q3 2026.
-
RTW Investments Equity Commitment and Warrants
RTW Investments committed to purchase at least $5 million of common stock and received warrants for 375,000 shares at a $4.00 exercise price, while extending the Anaphylm marketing approval deadline to June 30, 2027.
Analysis · AQST · Life Sciences
Aquestive Therapeutics reported significantly improved first-quarter financials, with a 66% revenue increase and a substantial reduction in net loss. Critically, the company secured a new $150 million debt facility post-quarter, which was immediately used to refinance existing high-interest debt and provides a much-needed capital runway. This financing event, coupled with ongoing progress on the Anaphylm NDA resubmission, addresses key liquidity and regulatory concerns. While challenges persist with Libervant's market access due to litigation, the overall financial and operational updates are highly positive, indicating a stronger position for future product development and commercialization.
At the time of this filing, AQST was trading at $4.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $513.3M. The 52-week trading range was $2.12 to $7.55. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.